RedHill Biopharma Ltd (RDHL) - Financial and Strategic SWOT Analysis Review

October 2021 | 53 pages | ID: R8E46D05C83EN
GlobalData

Abstracts

RedHill Biopharma Ltd (RDHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

RedHill Biopharma Ltd (RedHill) is a specialty biopharmaceutical company that develops and commercializes therapeutics for gastrointestinal (GI) diseases and cancer. The company’s commercial product portfolio consists of branded prescription drugs including a combination of omeprazole, amoxicillin and rifabutinomeprazole; naloxegol; and rifamycin. It is investigating its pipeline candidates for the treatment of crohn's disease, non-tuberculous mycobacterial infection (NTM) infections, gastroenteritis, gastritis, irritable bowel syndrome with diarrhea (IBS-D), bowel cleanser, cancer and novel corona virus disease (COVID-19). The company has a subsidiary in the US. RedHill is headquartered in Tel Aviv, Israel.

RedHill Biopharma Ltd Key Recent Developments

Sep 02,2021: RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences
Aug 26,2021: RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights
Jun 10,2021: RedHill Biopharma Notice of Annual General Meeting of Shareholders
Jun 09,2021: RedHill Biopharma to Present at the BIO Digital International Convention
Jun 08,2021: RedHill concludes enrolment in Phase II/III Covid-19 drug trial

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

RedHill Biopharma Ltd - Key Facts
RedHill Biopharma Ltd - Key Employees
RedHill Biopharma Ltd - Key Employee Biographies
RedHill Biopharma Ltd - Major Products and Services
RedHill Biopharma Ltd - History
RedHill Biopharma Ltd - Company Statement
RedHill Biopharma Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Affiliate

SECTION 2 – COMPANY ANALYSIS

Company Overview
RedHill Biopharma Ltd - Business Description
Product Category: Movantik
Performance
Product Category: Other revenues
Performance
R&D Overview
RedHill Biopharma Ltd - Corporate Strategy
RedHill Biopharma Ltd - SWOT Analysis
SWOT Analysis - Overview
RedHill Biopharma Ltd - Strengths
RedHill Biopharma Ltd - Weaknesses
RedHill Biopharma Ltd - Opportunities
RedHill Biopharma Ltd - Threats
RedHill Biopharma Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
RedHill Biopharma Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 02, 2021: RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences
Aug 26, 2021: RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights
Jun 10, 2021: RedHill Biopharma Notice of Annual General Meeting of Shareholders
Jun 09, 2021: RedHill Biopharma to Present at the BIO Digital International Convention
Jun 08, 2021: RedHill concludes enrolment in Phase II/III Covid-19 drug trial
May 27, 2021: RedHill Biopharma reports first quarter 2021 financial results and operational highlights
Mar 11, 2021: RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021
Mar 05, 2021: RedHill to Present at Upcoming Conferences in March
Feb 09, 2021: RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences
Nov 12, 2020: RedHill Biopharma provides q3/2020 results and highlights, including 300% talicia prescription growth

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

RedHill Biopharma Ltd, Key Facts
RedHill Biopharma Ltd, Key Employees
RedHill Biopharma Ltd, Key Employee Biographies
RedHill Biopharma Ltd, Major Products and Services
RedHill Biopharma Ltd, History
RedHill Biopharma Ltd, Other Locations
RedHill Biopharma Ltd, Subsidiaries
RedHill Biopharma Ltd, Affiliate
RedHill Biopharma Ltd, Key Competitors
RedHill Biopharma Ltd, Ratios based on current share price
RedHill Biopharma Ltd, Annual Ratios
RedHill Biopharma Ltd, Annual Ratios (Cont...1)
RedHill Biopharma Ltd, Interim Ratios
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
RedHill Biopharma Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

RedHill Biopharma Ltd, Performance Chart (2016 - 2020)
RedHill Biopharma Ltd, Ratio Charts
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021